Therapeutic Effects of Switching to Anagliptin from Other DPP-4 Inhibitors in T2DM Patients with Inadequate Glycemic Control: A Non-interventional, Single-Arm, Open-Label, Multicenter Observational Study
DIABETES THERAPY（2023）
Key words
Diabetes mellitus,Type 2,Dipeptidyl peptidase IV inhibitors,Anagliptin,Comorbidities,Switching
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined